Scientific and Financial Planning

John S. Kovach. M.D. founded Lixte and has been its sole administrative officer. Dr. Kovach has directed leading National Cancer Institute–designated Comprehensive Cancer Centers at Mayo Clinic, Rochester, Minnesota and City of Hope National Medical Center, Los Angeles, California. He has extensive experience in medical oncology, anti-cancer drug pharmacology, and in applied medical research, particularly, the early evaluation of new anti-cancer drugs and the development and management of multi-disciplinary highly productive cancer research teams. Dr. Kovach, in consultation with Lixte's advisors and board, is responsible for the selection and prioritization of the scientific directions and goals of Lixte.

Francis Johnson, Ph.D. is a chemical pharmacologist who consults for and collaborates with Lixte Inc. in the systematic development of new anti-cancer substances based on a knowledge of defined biochemical abnormalities in specific types of human cancers. Dr. Johnson is a highly experienced synthetic organic chemist who has broad knowledge of pharmacology. He is the principal inventor on approximately 70 patents many of which deal with pharmacologic agents and his academic research, which includes theoretical studies on stereochemistry, synthetic work on many natural products and extensive work on DNA damage, has been reported in more than 170 peer-reviewed publications. Dr. Johnson is also the president of Chem-Master International Inc., a company founded in 1994, that specializes both in the custom synthesis of chemical intermediates and in the development of new drug substances. Dr. Johnson spent the early part of his career working in the Eastern Research Laboratory, a research institute near Boston, run by the Dow Chemical Co. Since 1974 he has occupied Professorships in both Chemistry and in Pharmacological Sciences at Stony Brook University.

Gil N. Schwartzberg, JD, ScD (hon) was the Chief Executive Officer and Chairman of the Board of Directors of the City of Hope National Medical center, an NCI designated Comprehensive Cancer Center. Mr. Schwartzberg was the only person in the City of Hope’s 100-year history to hold both CEO and Board Chair positions. He is currently Chairman Emeritus for life. His leadership and perceptive insights into the complexities of integrating basic science research with state-of-the-art compassionate patient care and the accreditation of the Graduate School of Biological Sciences at City of Hope during his tenure as president, were recognized by that institution in 2003 by awarding Mr. Schwartzberg a Doctor of Science degree, the first such degree awarded by the graduate school. During his extensive career he has held positions of major responsibility in: law, biomedicine, banking, apparel/shoe manufacturing and fast food retailing. He has overseen the process by which over a dozen companies have become publicly traded, on all of the United States securities exchanges.